Genus (GNS) 주식 개요
Genus plc는 북미, 라틴 아메리카, 영국, 나머지 유럽, 중동, 러시아, 아프리카 및 아시아의 농부들에게 동물 유전학을 생산하고 판매합니다. 자세히 보기
GNS Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Genus plc 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | UK£24.78 |
| 52주 최고가 | UK£32.29 |
| 52주 최저가 | UK£18.90 |
| 베타 | 0.90 |
| 1개월 변동 | -3.28% |
| 3개월 변동 | -20.96% |
| 1년 변동 | 22.07% |
| 3년 변동 | -0.96% |
| 5년 변동 | -50.93% |
| IPO 이후 변동 | 1,735.56% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 18
GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside
Analysts have reduced their fair value estimate for Genus from about £31.63 to roughly £31.28. This reflects a combination of slightly softer revenue growth assumptions, a modestly higher discount rate, and expectations for a stronger profit margin profile supported by a mix of bullish and neutral recent research views.
내러티브 업데이트 • May 03
GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside
Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.내러티브 업데이트 • Apr 19
GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside
Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.
내러티브 업데이트 • Apr 04
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.내러티브 업데이트 • Mar 20
GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside
Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.Recent updates
내러티브 업데이트 • May 18
GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside
Analysts have reduced their fair value estimate for Genus from about £31.63 to roughly £31.28. This reflects a combination of slightly softer revenue growth assumptions, a modestly higher discount rate, and expectations for a stronger profit margin profile supported by a mix of bullish and neutral recent research views.내러티브 업데이트 • May 03
GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside
Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.내러티브 업데이트 • Apr 19
GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside
Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.내러티브 업데이트 • Apr 04
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.내러티브 업데이트 • Mar 20
GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside
Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.내러티브 업데이트 • Mar 06
GNS: China JV And Gene Editing Progress Will Support Medium Term Upside
Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.내러티브 업데이트 • Feb 20
GNS: Gene Editing Execution And Regulatory Timelines Will Constrain Medium-Term Upside
Analysts have raised their fair value estimate for Genus from £24.00 to £25.50, reflecting updated assumptions on revenue growth, profit margins and the potential of its gene editing technology as highlighted in recent research. Analyst Commentary Recent street research on Genus highlights a mix of optimism around its gene editing platform and caution around how that potential is reflected in the share price.내러티브 업데이트 • Feb 06
GNS: Gene Editing Progress And China JV Will Shape Balanced Medium Term Outlook
Genus's updated analyst price target reflects a modest uplift in estimated fair value to £30.82, supported by higher assumed revenue growth and a richer future P/E multiple, even as analysts factor in a slightly higher discount rate and softer profit margins. Analyst Commentary Recent Street research on Genus points to a generally constructive stance, with analysts revisiting their models and price targets as they reassess the company’s growth potential and execution risks.내러티브 업데이트 • Jan 23
GNS: Gene Editing Breakthrough Will Drive Medium Term Upside Potential
Narrative Update on Genus Analysts have lifted their price target on Genus to £31.00 from £29.00, citing the company's gene editing technology and its perceived medium term upside potential as key reasons for the change. Analyst Commentary Bullish analysts are highlighting Genus as a name with medium term upside potential, underpinned by its gene editing capabilities and recent supportive price target work.내러티브 업데이트 • Jan 08
GNS: Gene Editing Potential Will Drive Balanced Medium-Term Opportunity And Execution Risk
Narrative Update Analysts now see Genus as fairly valued in a range of £30.50 to £31.00. This reflects a modestly revised P/E assumption, slightly higher revenue growth and profit margin expectations, and a growing focus on the potential of its gene editing technology for medium term upside.분석 기사 • Jan 06
Calculating The Fair Value Of Genus plc (LON:GNS)
Key Insights Genus' estimated fair value is UK£21.95 based on 2 Stage Free Cash Flow to Equity Current share price of...내러티브 업데이트 • Dec 22
GNS: Gene Editing Platform Will Shape Balanced Medium-Term Upside And Execution Risks
Genus's analyst price target has been raised from about £18.80 to £24.00 per share as analysts highlight the upside from its gene editing platform and reaffirm Buy ratings alongside recent target hikes from major banks. Analyst Commentary Recent research updates underscore a constructive stance on Genus, with buy ratings supported by the view that its gene editing platform could materially expand medium term earnings power.내러티브 업데이트 • Dec 08
GNS: Gene Editing Platform Will Drive Medium Term Upside Despite Execution Risks
Analysts have nudged their price target on Genus higher to £31.00 from £29.00, citing increasing confidence in the medium term upside from its gene editing platform and a modest uplift in expected profitability, even as growth assumptions normalize slightly. Analyst Commentary Bullish analysts highlight that the uplift in price targets reflects growing conviction that Genus can translate its gene editing capabilities into sustained, above-market earnings growth over the medium term.내러티브 업데이트 • Nov 24
GNS: Future China Joint Venture Will Improve Near-Term Shareholder Returns
Analysts have increased their price target for Genus from £29.00 to £31.00. This reflects greater confidence in the company's outlook despite moderating growth forecasts and a slightly higher discount rate.분석 기사 • Nov 15
Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Genus plc ( LON:GNS ) is definitely a stock worth...분석 기사 • Oct 28
Genus (LON:GNS) Is Paying Out A Dividend Of £0.217
Genus plc's ( LON:GNS ) investors are due to receive a payment of £0.217 per share on 5th of December. Including this...분석 기사 • Oct 18
We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit
Genus plc's ( LON:GNS ) solid earnings announcement recently didn't do much to the stock price. Our analysis suggests...분석 기사 • Oct 11
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217
Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of December. This means...내러티브 업데이트 • Sep 10
FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream
The upward revision in Genus’s price target reflects improved analyst expectations, driven by notable increases in both forecast revenue growth (from 4.0% to 4.9% per annum) and net profit margin (from 7.88% to 8.73%), resulting in a new fair value of £27.97. What's in the News Genus and Beijing Capital Agribusiness Co. (BCA) have accelerated the formation of a Chinese joint venture to commercialise PRRS 2 Resistant Pig (PRP), with BCA holding 51% and Genus 49%.분석 기사 • Sep 07
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217
The board of Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of...분석 기사 • Jul 25
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise
Despite an already strong run, Genus plc ( LON:GNS ) shares have been powering on, with a gain of 25% in the last...분석 기사 • Jul 22
Estimating The Fair Value Of Genus plc (LON:GNS)
Key Insights The projected fair value for Genus is UK£25.58 based on 2 Stage Free Cash Flow to Equity Genus' UK£24.10...분석 기사 • May 10
Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Genus plc ( LON:GNS ) shareholders would be excited to see that the share price has had a great month, posting a 36...분석 기사 • Apr 18
An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued
Key Insights The projected fair value for Genus is UK£20.55 based on 2 Stage Free Cash Flow to Equity Genus is...
새로운 내러티브 • Feb 11
Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position
Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration.분석 기사 • Feb 01
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise
Genus plc ( LON:GNS ) shareholders are no doubt pleased to see that the share price has bounced 25% in the last month...분석 기사 • Nov 20
Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S
Genus plc's ( LON:GNS ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a strong buy right now compared...분석 기사 • Oct 23
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217
Genus plc ( LON:GNS ) will pay a dividend of £0.217 on the 6th of December. This payment means the dividend yield will...분석 기사 • Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings
The market for Genus plc's ( LON:GNS ) shares didn't move much after it posted weak earnings recently. We did some...분석 기사 • Sep 08
Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next
Genus plc ( LON:GNS ) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to UK£17.10...분석 기사 • Jun 16
The Price Is Right For Genus plc (LON:GNS)
Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right now...분석 기사 • Apr 20
Estimating The Fair Value Of Genus plc (LON:GNS)
Key Insights Genus' estimated fair value is UK£18.59 based on 2 Stage Free Cash Flow to Equity Genus' UK£17.18 share...분석 기사 • Mar 25
Is Genus (LON:GNS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Mar 05
With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For
Genus plc ( LON:GNS ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The drop...분석 기사 • Feb 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103
Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.103 per share on the 28th of March. The dividend...분석 기사 • Jan 17
Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult
Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 44x might make it look like a strong sell right now...분석 기사 • Dec 10
Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?
Key Insights The projected fair value for Genus is UK£15.63 based on 2 Stage Free Cash Flow to Equity Genus is...주주 수익률
| GNS | GB Biotechs | GB 시장 | |
|---|---|---|---|
| 7D | 3.2% | 1.4% | 2.5% |
| 1Y | 22.1% | 26.9% | 19.4% |
수익률 대 산업: GNS은 지난 1년 동안 26.9%의 수익을 기록한 UK Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: GNS은 지난 1년 동안 19.4%를 기록한 UK 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| GNS volatility | |
|---|---|
| GNS Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 11.9% |
| 10% least volatile stocks in GB Market | 3.1% |
안정적인 주가: GNS는 지난 3개월 동안 UK 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: GNS의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1994 | 3,190 | JK Kokke | www.genusplc.com |
Genus plc는 북미, 라틴 아메리카, 영국, 나머지 유럽, 중동, 러시아, 아프리카 및 아시아의 농부들에게 동물 유전학을 생산 및 판매합니다. 이 회사는 세 가지 부문으로 운영됩니다: Genus PIC, Genus ABS, Genus 연구 및 개발입니다. Genus 및 Bovec 브랜드로 낙농 및 육우 황소 정액과 배아를, PIC 브랜드로 돼지와 정액, 기술 서비스 및 자문을 제공합니다.
Genus plc 기초 지표 요약
| GNS 기초 통계 | |
|---|---|
| 시가총액 | UK£1.66b |
| 순이익 (TTM) | UK£47.50m |
| 매출 (TTM) | UK£672.00m |
34.9x
주가수익비율(P/E)2.5x
주가매출비율(P/S)GNS는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| GNS 손익계산서 (TTM) | |
|---|---|
| 매출 | UK£672.00m |
| 매출원가 | UK£402.40m |
| 총이익 | UK£269.60m |
| 기타 비용 | UK£222.10m |
| 순이익 | UK£47.50m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
Sep 10, 2026
| 주당순이익(EPS) | 0.71 |
| 총이익률 | 40.12% |
| 순이익률 | 7.07% |
| 부채/자본 비율 | 46.4% |
GNS의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
1.3%
현재 배당 수익률46%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 12:11 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/06/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Genus plc는 18명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Robert Chantry | Berenberg |
| Matthew Lloyd | BNP Paribas |
| Alexander Jones | BofA Global Research |